Literature DB >> 16751009

Chronic urticaria sera increase basophil CD203c expression.

Karen M Yasnowsky1, Stephen C Dreskin, Benjamin Efaw, David Schoen, P K Vedanthan, Rafeul Alam, Ronald J Harbeck.   

Abstract

BACKGROUND: Approximately 40% of patients with chronic idiopathic urticaria have antibodies to the alpha subunit of the high-affinity IgE receptor. CD203c is a basophil activation marker known to be upregulated by cross-linking of the FcepsilonRIalpha receptor and may serve as a useful marker to identify these patients.
OBJECTIVE: The primary objective was to assess the affect of sera from patients with chronic idiopathic urticaria on basophil CD203c expression. Secondary objectives were to correlate CD203c expression with basophil histamine release and size of the autologous serum skin test and to determine whether the mechanism is mediated by an IgG antibody.
METHODS: Sera were obtained from patients with chronic idiopathic urticaria and positive autologous serum skin test or negative autologous serum skin test and normal controls. Sera were incubated with donor whole blood. Activated basophils from whole blood were identified by flow cytometry on the basis of the presence of CD203c on high-expressing IgE positive cells.
RESULTS: Incubation of donor basophils with sera from patients with chronic idiopathic urticaria and positive autologous serum skin test demonstrated significant upregulation of CD203c. IgG depletion of representative sera from patients with chronic idiopathic urticaria resulted in significant decrease in CD203c expression on donor basophils. CD203c expression correlated with basophil histamine release and the size of the autologous serum skin test.
CONCLUSION: Sera from patients with chronic idiopathic urticaria and positive autologous serum skin test significantly upregulate basophil CD203c and correlate with basophil histamine release. CLINICAL IMPLICATIONS: This article describes an activation marker on basophils whose expression is increased by sera from patients with chronic idiopathic urticaria.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16751009     DOI: 10.1016/j.jaci.2006.02.016

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  28 in total

1.  The role of autoimmune testing in chronic idiopathic urticaria.

Authors:  Ravi K Viswanathan; Mark J Biagtan; Sameer K Mathur
Journal:  Ann Allergy Asthma Immunol       Date:  2012-03-21       Impact factor: 6.347

2.  [Cellular in-vitro assays. Applicability in daily routine].

Authors:  B Wedi; A Kapp
Journal:  Hautarzt       Date:  2010-11       Impact factor: 0.751

3.  Basophil CD203c levels are increased at baseline and can be used to monitor omalizumab treatment in subjects with nut allergy.

Authors:  Yael Gernez; Rabindra Tirouvanziam; Grace Yu; Eliver E B Ghosn; Neha Reshamwala; Tammie Nguyen; Mindy Tsai; Stephen J Galli; Leonard A Herzenberg; Leonore A Herzenberg; Kari C Nadeau
Journal:  Int Arch Allergy Immunol       Date:  2010-10-25       Impact factor: 2.749

Review 4.  Immunomodulatory approaches to the management of chronic urticaria: an immune-mediated inflammatory disease.

Authors:  Clifton O Bingham
Journal:  Curr Allergy Asthma Rep       Date:  2008-07       Impact factor: 4.806

5.  The relationship between total cellular content of CD203c and cell surface expression on human basophils.

Authors:  V Alexander; D MacGlashan
Journal:  Clin Exp Allergy       Date:  2015-06       Impact factor: 5.018

Review 6.  Pros and Cons of Clinical Basophil Testing (BAT).

Authors:  Hans Jürgen Hoffmann; Edward F Knol; Martha Ferrer; Lina Mayorga; Vito Sabato; Alexandra F Santos; Bernadette Eberlein; Anna Nopp; Donald MacGlashan
Journal:  Curr Allergy Asthma Rep       Date:  2016-07       Impact factor: 4.806

7.  Lack of basophil CD203c-upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticaria.

Authors:  Thamiris Palacios; Leland Stillman; Larry Borish; Monica Lawrence
Journal:  J Allergy Clin Immunol Pract       Date:  2015-12-24

8.  IgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcgammaRIIA and FcgammaRIIB.

Authors:  Carol T Cady; Maree S Powell; Ronald J Harbeck; Patricia C Giclas; James R Murphy; Rohit K Katial; Richard W Weber; P Mark Hogarth; Syd Johnson; Ezio Bonvini; Scott Koenig; John C Cambier
Journal:  Immunol Lett       Date:  2009-12-30       Impact factor: 3.685

9.  Progress and challenges in the understanding of chronic urticaria.

Authors:  Marta Ferrer; Allen P Kaplan
Journal:  Allergy Asthma Clin Immunol       Date:  2007-03-15       Impact factor: 3.406

10.  Chronic autoimmune urticaria: where we stand?

Authors:  C L Goh; K T Tan
Journal:  Indian J Dermatol       Date:  2009-07       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.